未登录

D

Deanna N. Parke

University of Tennessee Health Science Center

H指数:11

被引数:570

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Pyrimidine-Based Tubulin Inhibitor Shows Potent Anti-Glioblastoma Activity In Vitro and In Vivo

一种基于嘧啶的微管蛋白抑制剂在体外和体内显示出强效的抗胶质母细胞瘤活性

Pharmaceuticals 2025, Vol. 18, Page 1891

IF4.8

2025-12-150

OAAI

Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer

IF10.1

2024-08-010

OA

A novel stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor targeting microtubules (60c) is effective against taxane-resistant, metastatic breast cancer

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Glucocorticoid Receptors Drive Breast Cancer Cell Migration and Metabolic Reprogramming via PDK4

IF3.3

2023-05-2413

PRE

Sabizabulin shows anti-cancer efficacy in HER2+breast cancer and novel sabizabulin derivatives overcome paclitaxel-resistance in triple negative breast cancer

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer

秋水仙碱结合位点剂CH-2-77为抑制三阴性乳腺癌的有效微管蛋白抑制剂

MOLECULAR CANCER THERAPEUTICS

IF5.5

2022-05-028

OA

Design, Synthesis, and Biological Evaluation of Stable Colchicine-Binding Site Tubulin Inhibitors 6-Aryl-2-benzoyl-pyridines as Potential Anticancer Agents

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-08-1137

OA

Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis

BREAST CANCER RESEARCH AND TREATMENT

IF3

2021-07-0337

PREAI

Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling

MOLECULAR CANCER RESEARCH

IF4.7

2021-02-0318

OAAI

VERU-111, a novel orally bioavailable tubulin inhibitor, overcomes taxane resistance in metastatic triple-negative breast cancer

CANCER RESEARCH

IF16.6

2020-08-150

PRE

An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance

MOLECULAR CANCER THERAPEUTICS

IF5.5

2020-02-0633

OAAI

Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy

MOLECULAR PHARMACOLOGY

IF3

2019-07-0126

OAAI

Inhibition of creatine kinase metabolism represses invasion and sensitizes estrogen-receptor negative breast cancer cells to standard chemotherapies

CANCER RESEARCH

IF16.6

2019-02-150

PRE

HIF-1-dependent regulation of creatine kinase metabolism promotes breast cancer invasion and metastasis

CANCER RESEARCH

IF16.6

2017-07-010

PRE

ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models

ITGA6直接受缺氧诱导因子调节，并在转移性乳腺癌模型中富集肿瘤干细胞活性和侵袭

MOLECULAR CANCER

IF33.9

2016-03-22160

OAAI

Preclinical Characterization of a Novel Diphenyl Benzamide Selective ERα Agonist for Hormone Therapy in Prostate Cancer

IF3.3

2012-03-0110

OAAI

Biological Activity of 4-Substituted Methoxybenzoyl-Aryl-Thiazole: An Active Microtubule Inhibitor

CANCER RESEARCH

IF16.6

2011-01-0233

OAAI